Payment overview · 2025
General Payments
$1,845.51
99 reported records · 14 companies
Healthcare provider profile · identity verified
Athanasios G. Papastamelos, DO
Allopathic & Osteopathic Physicians|Internal Medicine · LINWOOD, NJ · NPI 1821051277
Verified facts
What the public records show
CMS Open Payments records show Athanasios G. Papastamelos, DO received $1,845.51 in general payments during 2025 across 99 reported records.
ABBVIE INC. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arikayce, Biktarvy, Dovato, Teflaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEFLARO as an associated drug or biological on 11895 records involving 6021 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Teflaro by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Biktarvy by this doctor in 2024.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arikayce by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Isentress by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gammagard Liquid by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $407.72 | 22.1% | 24 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $375.48 | 20.4% | 18 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $284.99 | 15.4% | 19 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $196.98 | 10.7% | 12 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $136.08 | 7.4% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.09 | 6.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.81 | 4.7% | 4 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $61.92 | 3.4% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $52.82 | 2.9% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $50.40 | 2.7% | 3 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $19.66 | 1.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.61 | 0.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.42 | 0.9% | 1 | 2025 |
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.53 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,845.51 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $229.96 | 9 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $221.51 | 13 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $196.98 | 12 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $158.78 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.09 | 1 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $120.07 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $111.54 | 7 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $85.81 | 4 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $70.94 | 5 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $65.14 | 4 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $61.92 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $54.49 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $52.82 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $50.40 | 3 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $44.81 | 3 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $31.66 | 2 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Arikayce arikayce |
2025 | Arikayce | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 80 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TEFLARO teflaro |
2025 | Teflaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | TEFLARO open payments reported associated product |
CMS Open Payments — General Payments 11895 supporting records · 6021 recipient NPIs · example record 1201352826 |
Teflaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Doxycycline Hyclate | Doxycycline Hyclate | 305 | 186 |
| Azithromycin | Azithromycin | 233 | 94 |
| Levofloxacin | Levofloxacin | 232 | 148 |
| Cefuroxime | Cefuroxime Axetil | 140 | 92 |
| Daptomycin | Daptomycin | 135 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 118 | 86 |
| Cefepime Hcl | Cefepime Hcl | 115 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 114 | 54 |
| Furosemide | Furosemide | 112 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 35 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 95 | 60 |
| Eliquis | Apixaban | 95 | 40 |
| Methylprednisolone | Methylprednisolone | 95 | 70 |
| Alprazolam | Alprazolam | 83 | 24 |
| Valacyclovir | Valacyclovir Hcl | 82 | 33 |
| Dovato | Dolutegravir Sodium/Lamivudine | 80 | suppressed |
| Fluconazole | Fluconazole | 76 | 49 |
| Omeprazole | Omeprazole | 74 | 35 |
| Lisinopril | Lisinopril | 72 | 28 |
| Ertapenem | Ertapenem Sodium | 65 | 14 |
| Atorvastatin Calcium | Atorvastatin Calcium | 63 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 21 |
| Mupirocin | Mupirocin | 58 | 34 |
| Losartan Potassium | Losartan Potassium | 56 | 26 |
| Montelukast Sodium | Montelukast Sodium | 56 | 23 |
| Prednisone | Prednisone | 56 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 14 |
| Metformin Hcl | Metformin Hcl | 47 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 22 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 46 | 46 |
| Lorazepam | Lorazepam | 45 | 13 |
| Clonidine Hcl | Clonidine Hcl | 44 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 17 |
| Tramadol Hcl | Tramadol Hcl | 43 | 19 |
| Pregabalin | Pregabalin | 42 | 15 |
| Allopurinol | Allopurinol | 40 | 13 |
| Metronidazole | Metronidazole | 40 | 30 |
| Sodium Chloride | 0.9 % Sodium Chloride | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 16 |
| Carvedilol | Carvedilol | 37 | 17 |
| Spironolactone | Spironolactone | 36 | 17 |
| Dexamethasone | Dexamethasone | 35 | 27 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 35 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 25 |
| Ethambutol Hcl | Ethambutol Hcl | 33 | 14 |
| Gentamicin Sulfate | Gentamicin Sulfate | 33 | 19 |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 31 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 30 | 28 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 16 |
| Gabapentin | Gabapentin | 29 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 18 |
| Isentress | Raltegravir Potassium | 29 | suppressed |
| Valsartan | Valsartan | 29 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 14 |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 17 |
| Epinephrine | Epinephrine | 24 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 23 | suppressed |
| Meropenem | Meropenem | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 15 |
| Isoniazid | Isoniazid | 22 | 14 |
| Ondansetron Odt | Ondansetron | 22 | 17 |
| Santyl | Collagenase Clostridium Hist. | 22 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 22 | suppressed |
| Linezolid | Linezolid | 21 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | 13 |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 12 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Klayesta | Nystatin | 17 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Etravirine | Etravirine | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Tivicay | Dolutegravir Sodium | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Teflaro | Ceftaroline Fosamil Acetate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Cefadroxil | Cefadroxil | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Darunavir | Darunavir | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,845.51 · 99 records | ABBVIE INC. | AUSTEDO XR, AVYCAZ, Arikayce, BREZTRI, Biktarvy, Brinsupri, CABENUVA, CAPVAXIVE, COLLAGENASE SANTYL, DALVANCE, DOVATO, EMBLAVEO, EVENITY, Epclusa, Fetroja, HYQVIA, MAVYRET, Mytesi, NUZYRA, PIFELTRO, RUKOBIA, TEFLARO, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, ZERBAXA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arikayce play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error